This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
I have no interest in any supplier named above.
The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.
On post #63 — agreed on the reasoning, with one qualification.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
If this contradicts something upthread, the upthread version may well be the better one.
Picking up post #63: that is the part I would want checked first.
Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.
Not the answer, but possibly the question that gets there.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
The literature is thinner on this than the confidence in the thread implies.
PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.
Narrowing post #70, because the general version has more than one answer.
Reporting rather than recommending, on Oral semaglutide bioavailability. What happened is above. Whether it should have is a different question and not one I am qualified to answer.
PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.
I would want to see it done twice before believing it once.
Post #72 and I disagree about the size of the effect, not about the direction.
PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.
Somebody will have a better source than mine, and I hope they post it.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.
This follows post #74 rather than contradicting it.
Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.
Adding a source would improve this post and I do not have one to hand.
Worth separating two things that post #76 runs together.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
Post #76 describes the usual case. This is about the unusual one.
Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.
The interesting part of this is the exception, and I do not understand the exception.
I read post #77 twice before replying, because I had assumed the opposite.
On Oral semaglutide bioavailability the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.
Where I would look next, rather than where I would stop.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
It is the kind of thing that is obvious once and never again.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
I would put a moderate confidence on that and no more.
Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.
Posted with less confidence than the sentence structure implies.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
A partial answer, offered because a partial answer beats none.
Noted, and I have changed what I was going to do on the strength of it.
Picking up post #85: that is the part I would want checked first.
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.
This is the sort of thing the wiki should carry and currently does not.
Narrowing post #89, because the general version has more than one answer.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
This is the sort of thing that ought to be settled and apparently is not.